BY002

N/A

Report date: 2026/03/19 20:00:18
NME

Base Information

Drug NameBY002
Drug Alias NameBY-002
ClassificationSmall molecules
Mechanisms of ActionHistone-lysine N-methyltransferase 2A modulatorsNucleophosmin modulators
TargetsHistone-lysine N-methyltransferase 2ANucleophosmin
Therapy Area/IndicationsLeukemiaNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesBeyang Therapeutics Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesThe First Affiliated Hospital Of Soochow University
Inactive CompaniesBeyang Therapeutics Co Ltd
Active IndicationsLeukemia
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A